Please ensure Javascript is enabled for purposes of website accessibility

Can Rite Aid Keep It Up?

By Rick Munarriz - Sep 23, 2013 at 6:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugstore operator was a big winner last week.

Shares of Rite Aid (RAD -4.92%) were one of last week's biggest winners, soaring 30% after another blowout quarter. The once profitless drugstore operator has now surprised the market by rattling off four consecutive profitable quarters. Analysts were braced for deficits in three of those periods, including last week's report.

Sales inched marginally higher to $6.3 billion, fueled by a 1.7% increase in same-store pharmacy sales that was more than enough to offset a few store closures over the past year. Rite Aid now has 4,604 locations.

Investors trying to play the all-weather nature of drugstores have turned their attention to CVS (CVS -1.29%) and Walgreen (WBA -2.75%), and rightfully so. They are substantially larger, and they have been consistently profitable. The yields of 2.3% at Walgreen and 1.5% at CVS also help woo income investors. These aren't necessarily huge payouts, but they certainly beat Rite Aid, which hasn't paid out a dividend since 1999.

However, Rite Aid investors are the ones riding high these days. The stock has soared fivefold since falling below $1 this past December. 

That's a pretty spectacular return out of any retailer, but it doesn't mean Rite Aid is expensive. Rite Aid has been juicing up its guidance along the way, and analysts have no choice but to try to catch up by raising their own estimates. 

Wall Street's now eyeing a profit of $0.22 a share for this fiscal year that ends in February and $0.30 a share for the following year. The stock may have soared 243% so far this calendar year, but it's trading at a surprisingly reasonable 15.6 times next year's earnings. That's actually the same forward earnings multiple that Walgreen is fetching. CVS is cheaper.

Rite Aid isn't perfect. Debt is still clocking in at more than $6 billion. That's not as problematic as it was a year ago, given that the chain now expects to generate at least $1.24 billion in adjusted EBITDA this year. However, that's heavy leverage that needs to be noted.

We also can't ignore that non-pharmacy comps actually dipped 0.3% in its latest quarter. Rite Aid's turnaround has been largely the handiwork of cutting costs and improving margins. The real cheers will come when sales outpace inflation growth. After all, even looking out to next year, analysts are eyeing only 1% in top-line growth.

Rite Aid has still come a long way, and that's why a seemingly dead drugstore operator has been one of the biggest winners over the past year yet is still commanding a forward earnings multiple in the mid-teens. 

It can keep it up if it continues to deliver market-thumping results through improving margins, but sooner or later it's going to have to start becoming as popular with customers as it has been with investors over the past year. 

Longtime Fool contributor Rick Munarriz and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rite Aid Corporation Stock Quote
Rite Aid Corporation
$10.53 (-4.92%) $0.55
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
$40.88 (-2.75%) $-1.16
CVS Health Corporation Stock Quote
CVS Health Corporation
$105.06 (-1.29%) $-1.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.